| Host: |
HEK293 cells |
| Reactivity: |
SARS-CoV-2 |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-SARS-CoV-2 Spike S1+S2 ECD (S-ECD)-C-His & Avi protein was developed from hek293 cells and has a target region of C-His & Avi. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4 or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Spike S1+S2 ECD at 2 Mu g/mL (100 Mu L/well) can bind Recombinant Human ACE2 with a linear range of 0.15-3.03 ng/mL. |
| Immunogen: |
Recombinant SARS-CoV-2 (2019-nCoV) S1+S2 ECD (S-ECD) Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence Val16-Glu1188 of SARS-COV-2 (2019-nCoV) S1+S2 ECD (S-ECD) (Accession #QHD43416.1) fused with a 6 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
